These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21526620)

  • 21. HIV/AIDS care and treatment in sub-Saharan Africa.
    Kassaye SG; Katzenstein D
    AIDS Rev; 2003; 5(4):195-204. PubMed ID: 15011998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
    Wirden M; Lambert-Niclot S; Marcelin AG; Schneider L; Ait-Mohand H; Brunet C; Angleraud F; Amard S; Katlama C; Calvez V
    AIDS; 2009 Jan; 23(1):95-9. PubMed ID: 19050391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology of antiretroviral drug resistance in drug-naïve persons.
    Geretti AM
    Curr Opin Infect Dis; 2007 Feb; 20(1):22-32. PubMed ID: 17197878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong.
    Yam WC; Chen JH; Wong KH; Chan K; Cheng VC; Lam HY; Lee SS; Zheng BJ; Yuen KY
    J Clin Virol; 2006 Apr; 35(4):454-7. PubMed ID: 16386461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa.
    Barth RE; Wensing AM; Tempelman HA; Moraba R; Schuurman R; Hoepelman AI
    AIDS; 2008 Oct; 22(16):2210-2. PubMed ID: 18832885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
    Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
    Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
    Descamps D; Chaix ML; Montes B; Pakianather S; Charpentier C; Storto A; Barin F; Dos Santos G; Krivine A; Delaugerre C; Izopet J; Marcelin AG; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Tamalet C; Cottalorda J; Desbois D; Calvez V; Brun-Vezinet F; Masquelier B; Costagliola D;
    J Antimicrob Chemother; 2010 Dec; 65(12):2620-7. PubMed ID: 20965891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
    Holguín A; Ramirez de Arellano E; Rivas P; Soriano V
    AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world.
    Bennett DE
    Curr Opin Infect Dis; 2006 Dec; 19(6):607-14. PubMed ID: 17075338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa.
    van Zyl GU; Cotton MF; Claassen M; Abrahams C; Preiser W
    Pediatr Infect Dis J; 2010 Apr; 29(4):370-1. PubMed ID: 19935449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.